Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients are aged greater than 20 years who have H. pylori infection without prior eradication therapy and are willing to receive the sequential therapy will be eligible for enrollment.~Exclusion Criteria:~1. children and teenagers aged less than 20 years,~2. history of gastrectomy,~3. gastric malignancy, including adenocarcinoma and lymphoma,~4. previous allergic reaction to antibiotics (amoxicillin, clarithromycin, levofloxacin, metronidazole) and prompt pump inhibitors (lansoprazole),~5. contraindication to treatment drugs,~6. pregnant or lactating women,~7. severe concurrent disease,~8. Patients who cannot give informed consent by himself or herself.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Group A: Sequential therapy for 14 days D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bid
- Group B: Sequential therapy for 10 days (Type: EXPERIMENTAL): None
- Group C: Triple therapy for 14 days (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).